Overview

• Migraine is a disabling neurological disease, ranked among the top global causes of disability and affecting millions across all ages with a marked predominance in women.
• New preventive and acute options since 2011 include botulinum toxin, anti‑CGRP monoclonal antibodies and gepants, yet coverage and availability remain uneven in countries such as Argentina.
• In Spain, more than 1.5 million people live with chronic migraine, while in Argentina roughly 9–9.5% of the population—over 4 million—are affected, with many underdiagnosed or undertreated.
• Pediatric specialists estimate 7–10% of children and adolescents experience migraine, with school stress, sleep disruption, fasting, screens and certain foods noted as frequent triggers.
• Experts warn against self‑medication and medication overuse, citing risks such as rebound headaches and vascular complications from some drugs, and they advise clinical evaluation by specialists, with many patients requiring consultations with multiple clinicians before diagnosis.